Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.43 - $48.6 $415,044 - $524,880
-10,800 Reduced 42.69%
14,500 $637,000
Q1 2024

May 15, 2024

SELL
$43.78 - $63.86 $985,050 - $1.44 Million
-22,500 Reduced 47.07%
25,300 $1.27 Million
Q4 2023

Feb 14, 2024

BUY
$36.35 - $63.02 $497,995 - $863,374
13,700 Added 40.18%
47,800 $2.89 Million
Q3 2023

Nov 14, 2023

BUY
$48.35 - $61.26 $1.65 Million - $2.09 Million
34,100 New
34,100 $1.94 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.77B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.